Another study of clotting and COVID vaccinesTagged:
Another study has come out, comparing clotting risks of COVID-19 and various vaccines versus each other. What are the risks? And can we interpret the study the obvious way, or not?
Thrombosis and you
Everybody’s worried about thrombosis, now that the US has paused the JnJ vaccine and similar cautions have cropped up for the AZ/OX vaccine in Europe. Both of those are viral vector vaccines, and one dark suspicion is that this is a “class effect”, i.e., all viral vector vaccines might have thrombosis problems. As the only other viral vector vaccines currently in existence are for Ebola, we do not yet have sufficient evidence to conclude this.
Even more strangely, people worry about the risk of blood clots from the Pfizer and Moderna vaccines, which are mRNA vaccines and thus a totally different mechanism. It would be pretty weird if blood clotting was a class effect of immunization against COVID-19.
So… is it?
A new study of blood clotting in COVID patients and vaccinees
At first glance, it’s a beautiful thing: they synthesized medical records of vaccinees and COVID patients (and influenza vaccinees as a control) from the European Medicines Agency (EMA) monitoring in Europe, and from the TriNetX federated electronic health records from 59 healthcare agencies mostly in the US. Getting data from huge medical institutions like that is something of a minor triumph, navigating HIPAA and HL7, and lions & tigers & bears, oh my. Seriously: that’s a boatload of work, and deserves respect.
The populations were huge: 500k COVID patieents, 480k mRNA vaccinees, and a whopping 34 million AZ/OX vaccinees. (They did not evaluate the JnJ vaccinees.) As a statistician always concerned whether a study is has adequate statistical power, this gives me a happy.
Just to be very thorough, they looked at CSVT as well as portal vein thrombosis (PVT, in the liver). I like the thorough approach. Whichever way the conclusion comes out here, I’m starting to like these guys.
They curiously don’t present their main result in a table, forcing me to dig it out of the text. (If I were a referee here, that would be a rather pointed bit of advice: never make your reader hunt for your conclusion; make it painfully obvious!) But, ok… after a bit of excavation of word salad, we find they report on CVT event rates within 2 weeks after diagnosis with COVID (or flu, as a control) or vaccination.
The resulting CVT event rates and their 95% confidence limits were (pp 2-3):
|Medical event||CVT / million||95% LCL||95% UCL|
|COVID-19 mRNA vaccine||4.1||1.1||14.9|
Figure 1 from p 13, shown here, presents this data graphically, along with the exact population sizes studied. Figure S2, p 22 in the supplement, shows the highly significant result with Fisher’s Exact test between the COVID-19 cohort and the vaccinee cohort, i.e., getting vaccinated however you make that happen lowers your risk compared to getting COVID-19. (Notably, they do not test statistical significance of CVT rates between mRNA vaccines vs the AZ/OX vaccine, for reasons we explore below.)
Their conclusion is one with which it’s quite easy to agree, namely that getting vaccinated is hella better than getting COVID-19:
These data show that the incidence of CVT issignificantly increased after COVID-19,andgreater than that observed with BNT162b2 and mRNA-1273 COVID-19 vaccines.
Some cautions and some pushback
Now, the thing that’s getting some nervous side-eye here is that rows 3 & 4 of the table above show the CVT clotting risk of the mRNA vaccines and the AZ/OX viral vector vaccine to be comparable! That’s… peculiar!
Surely, since the clotting events were noticed and so loudly reported for the AZ/OX and JnJ vaccines, they would have been similarly reported for the Pfizer or Moderna vaccines if they had been observed? Already the dark corners of the internet are forming conspiracy theories about the government lying about adverse events…
First, let’s note that the paper’s authors themselves want to disabuse you of thinking this comparison is valid. From their conclusions section, the tell us that the various populations data-mined from EMR systems are not especially well matched. That makes a difference when some places are preferntially vaccinating the elderly, while others are not:
First, the magnitude of the COVID-19 risk versus the population baseline, or versus influenza, is not based on cohorts which were matched for age or other demographic factors. For the same reason, we cannot conclude that the mRNA vaccines studied here are associated with an increased riskof CVT; far larger samples are needed to address this question.
Also, this depends on the right thing being coded into the EMR databases, and being federated into a unified database utterly without error. This is clearly a problem; anybody who’s wrestled with ICD10 codings and HL7 systems probaby still has nightmares about it:
Second, we have no information about diagnostic accuracy or completeness, though this is likely to be less of an issue for CVT or PVT compared to many diagnosessince radiological confirmation is typically needed.
Also, we don’t have lab tests on whether these CVT events are even comparable. We could be comparing apples and oranges… or apples and sledgehammers:
Third, the absence of key haematological laboratory data from many patients limits our ability to comment on whether the mechanism of CVT after COVID-19 is likely to be similar or different from that observed after ChAdOx1 nCoV-19, especially regarding anti-platelet factor 4 (PF4) antibodies (Greinacher et al 2021; Schultz et al 2021).
Also, the EMA monitoring system and the EHR network in the US are just fundamentally different, so we’re skating on ice so thin it might as well be surface tension:
Finally, we cannot directly compare the risks of CVT associated with ChAdOx1 nCoV-19 with any of the other vaccines, or with COVID-19, since we are using data collected by the EMA monitoring system, not from the electronic health records network. (No patients in the network had received ChAdOx1 nCoV-19, reflecting the fact that the network is almost entirely US-based).
On the one hand: gee, that’s too bad. On the other: this is an example of scrupulous scientific honesty, and you should be applauding now. (Though doing so sadly, regretting the study isn’t what we all want it to be.)
There was of course pushback from other sectors, as well. I’m not a fan of the general media for this short of thing. But since STAT News doesn’t have an article up yet on this, I turned to a CBS news article . Slightly to my (pleasant) surprise, it turned out to be pretty good.
Pfizer commented on the confusing study design (presumably for the issues the authors themselves raised above):
Pfizer said that its own “comprehensive assessment of ongoing aggregate safety data… provided no evidence to conclude that arterial or venous thromboembolic events, with or without thrombocytopenia, are a risk associated with the use of our COVID-19 vaccine.”
Pfizer noted that a CDC review of data had detected slightly more cases of CVT in people given the Johnson & Johnson vaccine in the U.S., but “no similar findings have been observed with the authorized Pfizer-BioNTech vaccine.”
Tony Fauci, peripatetic head of NIAID, said it had “many many… procedural gaps”:
“Suggesting that the complication [CVT] following one vaccine is similar to that of the other… it is impossible, the way this study was designed and conducted, to make that determination”
“that confusion will be straightened out and it will be clear that you cannot make any statement, the way this is designed, about the adverse events following the vaccination with the mRNA comparing to anything else.”
But everybody agreed with the main conclusion: getting vaccinated is better than getting COVID!
The Weekend Conclusion
While worth watching, the comparison of CVT risk between mRNA and AZ/OX vaccines is probably not something to take seriously yet, unless it’s confirmed in more homogeneous datasets.
But the story on CVT risk for COVID-19 patients vs vaccinees is clear: get yourself vaccinated!
Notes & References
1: Oxford University News & Events, “Risk of rare blood clotting higher for COVID-19 than for vaccines”, Oxford Press Releases, 2021-Apr-15.↩
2: M Taquet, et al., “Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine”, Oxford preprit shared on OSF.io, retrieved 2021-Apr-16.↩
3: T Reals & S Berriman, “Study shows vaccines carry much lower risk of blood clots than COVID-19”, CBS News, 2021-Apr-16. ↩